(Alliance News) - Incanthera PLC on Friday reported a widened annual loss in a "very important year" for the company as it continued commercial discussion for its skin cancer asset, Sol.
In the financial year that ended March 31, Incanthera reported a pretax loss of GBP1.1 million, widened from GBP1.0 million the previous year.
The company said, alongside the development of Sol, it invested in its infrastructure and its market positioning during the year. This included establishing laboratory facilities in Sheffield and manufacturing commercial samples of Sol.
Looking forward, Incanthera said it hopes to conclude a deal for Sol and announce new avenues for progression and expansion.
Shares in Incanthera were untraded on AQSE at 6.5 pence on Friday morning in London. The last trade was at 5.0p on Wednesday.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.